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Synaptopathy is an increasingly popular term used 
to define a cellular event occurring in an early stage 
of many neurodegenerative, neurodevelopmental and 
psychiatric disorders. Such synaptic dysfunction is closely 
related to cognitive impairment. Nowadays, it is assumed 
that neurodegenerative diseases, including Alzheimer’s 
disease (AD), are synapse-related pathologies (defined 
as “synaptopathy”) in which misfolded proteins lead 
to synaptic dysfunction and loss, an event that precedes 
extensive aggregation of proteins (such as Aβ-oligomers, 
Phospho-Tau and synuclein) in the brain parenchyma. 
However, the relationship between protein aggregation 
and synapses loss remains unclear. Among brain diseases, 
AD synaptopathy, occurring at a very early stage of the 
pathology and it is clearly detectable already in patients 
with mild cognitive impairment (MCI), is the most 
studied. 
The spine-pathology represents a key event of this 
disease and offer an intriguing possibility to tackle AD. 
According to the amyloidogenesis hypothesis, altered Aβ 
species are the primary cause of spine dysfunction and find 
a way to prevent Aβ toxicity represents an important target 
for therapeutic intervention against synaptopathy. 
Recently, clinical observations have shown that a 
human mutation in the APP protein (A673V mutation) 
induces an early onset AD-type dementia in homozygous 
carriers, while heterozygous carriers are unaffected [1]. 
In the homozygous patients for A673V mutation, Aβ 
species were mutated and the APP cleavage generated Aβ 
mutated oligomers (Aβ
1-42
A2V), while in heterozygous 
the Aβ oligomers were a mix of both Aβ
1-42 
wildtype 
and Aβ
1-42
A2V mutated species. To better understand 
the impact of the A673V mutation in AD, we analyzed 
the synapto-toxic effect of oligomers formed by the 
aggregation of different Aβ peptides: 1) the wildtype Aβ
1-
42 
wt, 2) the mutated Aβ
1-42
A2V and 3) the combination 
of the two species: Aβ
1-42
MIX (Aβ
1-42
wt and Aβ
1-42
A2V) 
in a well characterized in vitro model of synaptopathy 
[2]. We proved that Aβ
1-42
A2V is more toxic than Aβ
1-42
wt 
oligomers and induce a more severe synaptic injury in 
hippocampal neurons. This result is in agreement with the 
human pathology of the AD A673V-homozygous carriers. 
Interestingly, the combination of wild type and mutated 
peptides (Aβ
1-42
MIX) did not exert any synaptic toxicity, 
confirming that the combination of both species, Aβ
1-42 
wt 
and Aβ
1-42
A2V peptides, hinders the Aβ-induced-toxicity 
Figure 1: Schematic diagram of the general structure of the excitatory synapses. Excitatory synapses are composed by the 
pre- and post-synaptic elements. In the post-synaptic element there is a specialization of the cell membrane called the postsynaptic density 
region (PSD), this zone contains a large number of scaffolding proteins. Among these proteins, PSD-95 is the more abundant and plays 
an important role in the localization of AMPA (red channels) and NMDA (green channel) receptors. Slight perturbations of the spine 
architecture lead to spine dysfunction and subsequently loss. The mechanism underling synaptic dysfunction is characterized by an initial 
reversible stage with a slight reduction of PSD-95 protein, NMDA and AMPA receptors that induces a synaptic dysfunction. Afterwards, 
a major decrease of PSD-95 occurs inducing an atrophy of the post-synaptic element that generate synaptic loss and eventually neuronal 
death.
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and counteracts synaptopathy in hippocampal neurons. 
Importantly, this is in accordance with the fact that the 
A673V-heterozygous carriers do not develop the disease. 
This suggests that the Aβ1-6A2V peptide is able to 
neutralize the toxicity of Aβ
1-42
wt. We hypothesize that the 
Aβ1-6A2V peptide (composed of the first 6 amino acids 
with the A673V human mutation sequence) could work as 
a β-sheet breaker peptide neutralizing the neurotoxic effect 
of oligomers on dendritic spine. This assumption is also 
validated by the different chemical-physical characteristics 
of the Aβ
1-42
A2V/Aβ
1-42
wt MIX. For example, these 
oligomers have different aggregation kinetic and produce 
smaller oligomers, which are unstable and not toxic [3]. 
To test the ability of Aβ1-6A2V peptide to neutralizing 
Aβ
1-42
wt toxic effect, we synthetized the short peptide 
Aβ1-6A2V and we tested its ability to counteract the 
Aβ
1-42
wt toxicity in hippocampal neurons. We found 
that the Aβ
1-42
A2V peptide exerted a neuroprotective 
effect against spine injury/loss, as expected. Intrigued 
by this in vitro neuroprotection, we aimed to validate 
the Aβ1-6A2V neuroprotective action in vivo and we 
generated a “bioactive cargo” by linking the six residues 
of A673V mutation (Aβ1-6A2V) with the TAT sequence 
(=Aβ1-6A2VTAT(D)) that allowed cell membrane, as 
well as Blood Brain Barrier, penetration. Noteworthy, 
the in vivo acute treatment with Aβ1-6A2VTAT(D)) 
conferred neuroprotection against synaptopathy in AD 
TgCRND8 mouse model [4], representing an innovative 
therapeutic tool to prevent AD. In another study, Di Fede 
and colleagues, performed a chronic treatment with the 
same peptide, Aβ1-6A2VTAT(D) in a different mouse 
model, the APP
swe
/PS1ΔE9. They showed that following a 
short-term treatment (2.5 months), the peptide prevented 
cognitive deterioration, Aβ aggregation and amyloid 
deposition in brain, while the longer chronic treatment (5 
months) rescued the cognitive impairment, attenuating the 
effect on Aβ production, but increasing amyloid burden. 
Such exacerbation of the amyloidogenesis was correlated 
to the TAT avidity for amyloid boost which may lead to 
a self-sustained recruitment of Aβ aggregates. This is in 
agreement with another study where the lentiviral TAT 
expression-construct injection into APP/PS1Tg mice 
increased Aβ oligomers as well as as the number and size 
of Aβ plaques [5]. On the contrary, the administration of a 
different TAT peptide, the RI-OR2-TAT, in APP
swe
/PS1ΔE9 
mice reduced the Aβ oligomer levels in brain parenchyma 
as well as amyloid-β burden in cerebral cortex and 
stimulated neurogenesis [6]. In addition, the TAT-BDNF 
peptide was able to reduce the Aβ level as well as Tau 
hyperphosphorylation and prevent spine injury in Tg2576 
mice express human Swedish mutant APP (APP
swe
) [7]. 
Finally, the first TAT chronic treatment was done with 
D-JNKI1 peptide (JNK inhibitor peptide) against AD in 
TgCRND8 mice (APP
swe/ind
) [8]. This was successful in 
reducing the amyloidogenic production of Aβ oligomers, 
powerfully rescued the synaptic dysfunction reverting 
completely the cognitive impairment, without increased 
Aβ plaques size and notably, without major side effects [8]. 
In summary the Aβ1-6A2VTAT(D) peptide is a powerful 
approach in preventing synaptopathy in preclinical studies. 
This first proof of concept needs further pharmacological 
investigations in order to define the safety of the cell 
permeable peptide (CCP). In fact, the CPP-strategy has 
been considered as a revolutionary breakthrough, but the 
CPP toxicity is not yet well understood. The safety is now 
the major issue and is directly related to CPP toxicity and 
degradation. It is now imperative to concentrate efforts to 
ensure translation of these finding to human.
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